

**DRUG PRIOR AUTHORIZATION COMMITTEE**

**September 20, 2018**

**TENTATIVE AGENDA**

MO Coalition for Community Behavioral Healthcare  
Lower Level CEO Room,  
221 Metro Drive, Jefferson City, MO

10:00 - 10:05	Welcome, Announcements and Introductions	Chairman
10:05 - 10:15	Minutes Review	Discussion/Approval
10:15 - 10:25	Pharmacy Program/ Budget Update	Mitch Ruth
10:25 - 10:35	DUR Update	Mark Roaseau

**Old Business**

10:35 – 10:45	<b>A. Implementation Schedule (Criteria for Previously Approved Clinical Edits, Step Therapies and <u>PA's</u>)</b>	Mark Roaseau
---------------	---------------------------------------------------------------------------------------------------------------------	--------------

**New Business**

10:45 – 11:00	<b>B. Proposed Actions - New Drug/Product Review (See website and Attached Summary)</b> <ul style="list-style-type: none"><li>i. Open Access</li><li>ii. Clinical Edit/Step Therapy</li><li>iii. PDL Products</li><li>iv. Prior Authorization<ul style="list-style-type: none"><li>• Discussion</li><li>• Public Hearing</li><li>• Decision</li></ul></li></ul>	Mark Roaseau
---------------	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--------------

11:00 – 11:45	<b>C. Clinical Edits</b> <ul style="list-style-type: none"><li><b>I. Aimovig® Clinical Edit</b><ul style="list-style-type: none"><li>• Discussion</li><li>• Public Hearing</li><li>• Decision</li></ul></li><li><b>II. Crysvita® Clinical Edit</b><ul style="list-style-type: none"><li>• Discussion</li><li>• Public Hearing</li><li>• Decision</li></ul></li><li><b>III. Jynarque® Clinical Edit</b><ul style="list-style-type: none"><li>• Discussion</li><li>• Public Hearing</li><li>• Decision</li></ul></li><li><b>IV. Palynziq® Clinical Edit</b><ul style="list-style-type: none"><li>• Discussion</li><li>• Public Hearing</li><li>• Decision</li></ul></li></ul>	
---------------	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--

**V. Oral Oncology 15 day Clinical Edit**

- Discussion
- Public Hearing
- Decision

11:45 – 1:00 **D. Preferred Drug List (PDL)**

**I. ACE Inhibitors/Calcium Channel Blocker Combination Agents**

- Discussion
- Public Hearing
- Decision

**II. ACE Inhibitors/Diuretic Combination Agents**

- Discussion
- Public Hearing
- Decision

**III. ADHD Therapy Agents**

- Discussion
- Public Hearing
- Decision

**IV. Angiotensin Receptor Blocker/Diuretic Combination Agents**

- Discussion
- Public Hearing
- Decision

**V. Angiotensin Receptor/Calcium Channel Blocker Combination Agents**

- Discussion
- Public Hearing
- Decision

**VI. Anticoagulant Agents: Oral and Subcutaneous**

- Discussion
- Public Hearing
- Decision

**VII. Antiplatelet Agents**

- Discussion
- Public Hearing
- Decision

**VIII. Beta Adrenergic Blockers and Diuretic Combination Agents**

- Discussion
- Public Hearing
- Decision

**IX. Calcium Channel Blocker Agents (Dihydropyridines)**

- Discussion
- Public Hearing
- Decision

- X. Calcium Channel Blocker Agents (Non-Dihydropyridines)**
  - Discussion
  - Public Hearing
  - Decision
- XI. Direct Renin Inhibitors and Combination Agents**
  - Discussion
  - Public Hearing
  - Decision
- XII. Lipotropic Agents: Homozygous Familial Hypercholesterolemia Products**
  - Discussion
  - Public Hearing
  - Decision
- XIII. Lipotropic Agents: Niacin Derivatives**
  - Discussion
  - Public Hearing
  - Decision
- XIV. Lipotropic Agents: Statins (HMG Co-A Reductase Inhibitors) and Statin Combination Products**
  - Discussion
  - Public Hearing
  - Decision
- XV. Lipotropic Agents: Triglyceride Lowering Agents**
  - Discussion
  - Public Hearing
  - Decision
- XVI. Proton Pump Inhibitor Agents**
  - Discussion
  - Public Hearing
  - Decision
- XVII. Pulmonary Arterial Hypertension (PHA) Agents: Inhaled/Injectable**
  - Discussion
  - Public Hearing
  - Decision
- XVIII. Pulmonary Arterial Hypertension (PHA) Agents: Oral**
  - Discussion
  - Public Hearing
  - Decision
- XIX. Sympatholytic Antihypertensive Agents**
  - Discussion
  - Public Hearing
  - Decision

**E. Preferred Drug List Classes for Dec/Jan**

- i. Process Discussion
- ii. Therapeutic classes/to be announced at meeting

1:00

**LUNCH**

1:15-1:30

**Program Utilization Information - Conduent Update**

Josh Moore

1:30-1:50

**Other Business**

- *“Top 25” Drugs by Cost/Claims*
- *Clinical Edit Summary Report*
- *Call Center Statistics*

*Informal comments will be accepted from members of the audience at various points in the agenda. Times noted are approximate, Agenda may move more quickly*

**NEXT MEETING: December 20, 2018**

MO Coalition for Community Behavioral Healthcare  
Lower Level CEO Room,  
221 Metro Drive, Jefferson City, MO